Canada Must Learn ‘Difficult Lessons’ From COVID-19
CGPA’s Keon Urges Strengthening Domestic Industry Amid Global Supply Chain
Executive Summary
Canadian policymakers must learn “difficult lessons” from the coronavirus pandemic and support measures to bolster domestic production and secure the country’s position as part of the global supply chain, according to CGPA president Jim Keon.
You may also be interested in...
Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
Canada’s CGPA Installs New Leaders
Canada’s off-patent industry association has looked to Pharmascience and Apotex for its new chair and vice-chair.
Canadian Body Calls For Investment In Domestic Production
In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.